Zumutor Biologics Inc

Zumutor Biologics Inc. is a biotechnology company based in Cambridge, Massachusetts. The company employs seven people and generates annual revenue exceeding $10,000. Zumutor Biologics Inc. is focused on developing innovative immuno-oncotherapeutics that aim to significantly improve cancer treatment by engaging natural killer (NK) cells. The company's core technology, INABLR™, is a proprietary antibody discovery platform that expedites the discovery and development of novel antibodies. Zumutor Biologics Inc. leverages its expertise in immuno-oncology and clinical development, guided by a world-class Scientific Advisory Board. Their lead asset, ZM008, is a groundbreaking antibody designed to target specific receptors that inhibit NK cell signaling, thereby stimulating NK cell activation and triggering a robust immune response against cancer. ZM008 is currently in development with an anticipated Investigational New Drug (IND) filing by the second quarter of 2022, followed by a Phase 1 clinical trial. Research and development for Zumutor Biologics Inc. is conducted in an ISO-certified laboratory located in Bangalore, India. To learn more about Zumutor Biologics Inc. and its groundbreaking work in immuno-oncology, visit their website at zumutor.com.